Osteonecrosi delle ossa mascellari farmaco-relata: ruolo nella pratica clinica endocrinologica-Reference-Cited by-同舟云学术

Osteonecrosi delle ossa mascellari farmaco-relata: ruolo nella pratica clinica endocrinologica

Published:2022-02-22 Issue:2 Volume:23 Page:156-162
ISSN:1590-170X
Container-title:L'Endocrinologo
language:it
Short-container-title:L'Endocrinologo

Author:

Brunetti Alessandro,Mazziotti Gherardo

Publisher

Springer Science and Business Media LLC

Subject

General Earth and Planetary Sciences,General Environmental Science

Link

https://link.springer.com/content/pdf/10.1007/s40619-022-01042-3.pdf

Reference28 articles.

1. Campisi G, Mauceri R, Bertoldo F et al. (2020) Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020. Int J Environ Res Public Health 17:1–15

2. Ruggiero SL, Dodson TB, Fantasia J et al. (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg 72:1938–1956

3. Fedele S, Bedogni G, Scoletta M et al. (2015) Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 53:13–17

4. Marx RE (2003) Pamidronate (aredia) and zoledronate (zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1118

5. Campisi G, Bedogni A, Fusco V (2020) Raccomandazioni clinico-terapeutiche sull’osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione (Versione 2.0; Luglio 2020). Palermo University Press, Palermo

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gestione clinica della terapia con Denosumab: in chi, quando e come interromperla;L'Endocrinologo;2023-02